BCL3 and acute myeloid leukemia: The discriminative capacity of BCL3 was revealed by ROC curve analysis, and the results indicated that BCL3 with and AUC value of 0.721 (95% CI: 0.56–0.84) might serve as a potential biomarker for distinguishing between AML and controls (P < 0.001, Fig. 2).